A recent article in Nature Reviews Drug Discovery (Nature Rev. Drug Discov. 11, 657–660; 2012)1 highlighted the outcome of the two largest Alzheimer's disease drug development programmes to date. Results from the Phase III clinical trials of two monoclonal antibodies — bapineuzumab and solanezumab — that target amyloid-β indicated little clinical benefit of immunological attack on amyloid-β at the dementia stage of sporadic disease2 (see the 12 December 2012 press release on the Lilly website).
Neither antibody demonstrated a favourable impact on the primary cognitive assessment scores and inventories of daily function in patients with mild to moderate Alzheimer's disease-related dementia. However, planned post-hoc pooled analyses of data from individuals with mild Alzheimer's disease-related dementia treated with solanezumab did show cognitive benefit, so the development of this agent for the treatment of Alzheimer's-related dementia will continue with a confirmatory clinical trial planned for launch later this year (See the 12 December 2012 press release on the Lilly website).
The negative primary analyses in these two programmes represent the culmination of a 'lost decade' in Alzheimer's disease therapeutic trials, with no substantial success since the approval of memantine. Studies of hypothesis-driven candidate disease modifiers such as anti-inflammatory drugs, secretase inhibitors and modulators, hormonal therapies, statins and other drugs have been disappointing. The clinical failure of the two leading γ-secretase inhibitors, semagacestat (see the 17 August 2010 press release on the Lilly website) and avagacestat (see the Bristol-Myers Squibb website), have added further gloom to the outlook.
The major approach to disease modification has been the targeting of amyloid-β accumulation in the brain. Genetic evidence strongly indicates that amyloid-β can drive the disease process, so reducing its production or promoting its clearance is an attractive aim3. Although accumulation of amyloid-β in the brain is probably multifactorial in late-onset sporadic Alzheimer's disease (in contrast to autosomal dominantly inherited early-onset Alzheimer's disease), it is plausible that amyloid-targeted interventions may yield clinical benefit in all forms of Alzheimer's disease if they are initiated very early, before severe synaptic dysfunction and irreversible widespread cell loss and neurodegeneration have occurred4. Indeed, the recent discovery that a genetically determined reduction in amyloid-β peptide production by 40% provides dramatic protection against Alzheimer's disease5 further suggests that the clinical failures may relate primarily to the timing of the intervention.
Consensus regarding the pathophysiological processes that underlie Alzheimer's disease progression is reflected by the newly revised criteria for diagnosing Alzheimer's disease-related dementia, mild cognitive impairment and preclinical disease6. In particular, the concept of a biomarker-defined pre-symptomatic stage of Alzheimer's disease provides a foundation for early-stage clinical trials. Based on the prevailing view that the accumulation of amyloid-β in the brain is a principal inciting event in Alzheimer's disease pathophysiology, this early stage of the disease can be recognized by abnormal amyloid positron emission tomography (PET) scans or a reduction in the levels of amyloid peptides in cerebrospinal fluid.
Although at this stage individuals are normal from a clinical perspective, they can be accurately identified and disease progression can be tracked using dynamic biochemical and imaging biomarkers as well as tests of cognitive performance7,8. Although it remains to be proven whether all individuals with brain amyloidosis will progress to symptomatic Alzheimer's disease if they live sufficiently long, this is a plausible hypothesis that is consistent with the available autopsy and biomarker data9. Indeed, analyses of data from multiple studies indicate that asymptomatic individuals with amyloid-β accumulation in the brain show faster cognitive decline than similar individuals without amyloidosis.
Indeed, Alzheimer's disease progression may involve a long, symptom-free phase preceding gradual cognitive, functional and behavioural decline that is functionally adaptive and plausibly reversible. Therefore, efforts to develop disease-modifying treatments may require clinical trials to be conducted much earlier in the disease process. Studies can be powered based on the hypothesis that amyloid-targeted or other disease-modifying interventions can reduce the rate of amyloid-mediated decline towards normal trajectories. It is possible that regulatory authorities the in United States and Europe could approve a drug for the treatment of preclinical Alzheimer's disease on the basis of a single, primary cognitive end point that is supplemented by a panel of biomarkers and postmarketing studies to support clinical benefit (Table 1; Fig. 1); see the US Food and Drug Administration (FDA)'s draft guidance. This contrasts with the current requirement for cognitive assessments combined with functional and/or global assessments.
Using these principles, three early-stage trials will launch within the next year, one in patients with sporadic disease (see the article titled “NIH-supported Alzheimer's studies to focus on innovative treatments” on the US National Institutes of Health website) and two in families with mutations associated with autosomal dominant Alzheimer's disease (ClinicalTrials.gov identifier: NCT01760005; see the 21 May 2012 news article on the Alzheimer Research Forum). These clinical trials will use a composite cognitive end point. In addition, a pilot longitudinal biomarker study in individuals with Down's syndrome is planned, as a foundation to clinical trials in this group of patients who are at a high risk of developing Alzheimer's disease10.
It is more likely that these secondary prevention trials, rather than the recent dementia-stage trials, will demonstrate the beneficial effects of anti-amyloid therapy on disease progression. But it is plausible that the most effective intervention will be primary prevention in individuals at risk (by virtue of age, genetics and/or other factors) but without biomarker-based evidence of Alzheimer's disease neurobiology. Therefore, additional collaborative biomarker studies are required to inform the design of such clinical trials. Our long-term vision includes risk factor and biomarker monitoring of the ageing population, with the use of effective anti-amyloid (and perhaps neuroprotective) therapies that will succeed in quelling the Alzheimer's disease epidemic. Recent trial results have been disappointing, but we find cause for optimism.
References
Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657–660 (2012).
Sperling, R. et al. A randomized, double-blind placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ε4 carriers. European Federation of Neurological Societies [online], (Stockholm, Sweden; 2012).
Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
Sperling, R. A., Jack, C. R. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).
Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).
Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280–292 (2011).
Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560–574 (2010).
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease; the Dominantly Inherited Alzheimer Network. N. Engl. J. Med. 367, 795–804 (2012).
Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging. 31, 1275–1283 (2010).
Ness, S. et al. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nature Rev. Drug Discov. 11, 655–656 (2012).
Acknowledgements
P.S.A.'s work is supported by grants from the US National Institute on Aging of the US National Institutes of Health. B.V.'s work is supported by Gerontopole, CHU, INSERM UMR 1027, University of Toulouse. H.H.'s work is supported by grants from the Katharina-Hardt-Foundation, Bad Homburg, Germany.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Paul S. Aisen serves on a scientific advisory board for NeuroPhage; he has served as a consultant to Elan Corporation, Wyeth, Eisai, Schering-Plough, Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck & Co., Roche, Amgen, Genentech, Abbott, Pfizer, Novartis, Bayer, Astellas Pharma, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, Medivation, Ichor, Toyama, Lundbeck, Biogen Idec, iPerian, Probiodrug, Somaxon, Biotie, Anavex and Kyowa Hakko Kirin Pharma; and he receives research support from Eli Lilly and Company and Baxter International.
Bruno Vellas has served as a consultant to Elan Corporation, Schering-Plough, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Roche, Genentech, Pfizer, Novartis, AstraZeneca, Janssen, Medivation, Nestle and Nutritia; he receives research support from Pierre Fabre, and has received several grants from the European Commission and the Public Health Research Consortium programme.
Harald Hampel has, during the past two years (2011 to 2013), received lecture honoraria and/or research grants and/or travel funding and/or participated in scientific advisory boards and/or served as a consultant to diagnostic, biotechnology and pharmaceutical companies involved in the manufacture and marketing of biomarkers and/or diagnostics and/or drugs or medicinal products for cognitive impairment and/or Alzheimer's disease. These companies include Boehringer-Ingelheim, Bristol-Myers Squibb, Elan Corporation, Wyeth, Novartis, Eisai, Pfizer, Schwabe, Sanofi-Aventis, Roche Pharmaceuticals and Diagnostics, GE Healthcare, Astra-Zeneca, Avid, Eli Lilly and Company, Janssen-Cilag, Merz Pharmaceuticals, GlaxoSmithKline-Biologicals, Jung-Diagnostics and Thermo Fisher Scientific Clinical Diagnostics. He is co-inventor in pending patent submissions relating to biological markers and/or diagnostics but has not received any royalties.
Rights and permissions
About this article
Cite this article
Aisen, P., Vellas, B. & Hampel, H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov 12, 324 (2013). https://doi.org/10.1038/nrd3842-c1
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3842-c1
This article is cited by
-
Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank
Communications Medicine (2023)
-
Designing the next-generation clinical care pathway for Alzheimer’s disease
Nature Aging (2022)
-
The Amyloid-β Pathway in Alzheimer’s Disease
Molecular Psychiatry (2021)
-
Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment
Alzheimer's Research & Therapy (2016)
-
Plasma protein biomarkers of Alzheimer’s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes
Translational Psychiatry (2015)